# Arrakis Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/arrakis-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Waltham, US
- Website: www.arrakistx.com
- Total disclosed funding: $28M
- Latest round: Series B (Apr 10, 2019)
- Investors on record: 14

## About

Arrakis Therapeutics, Inc. is a biotechnology company focused on developing RNA-targeted small-molecule medicines designed to treat a variety of diseases through innovative genetic therapies.Founded in 2015 and headquartered in Waltham, Massachusetts, Arrakis Therapeutics, Inc. is dedicated to the development of RNA-targeted small-molecule (rSM) therapies. The company has received a total of two funding rounds, with the latest being a Series B round in April 2019, where they raised USD 15.00 mn. Key investors include Advent Life Sciences, Alexandria Venture Investments, and Pfizer Venture Investments, among others. CEO Michael Gilman leads the company, which has not undergone significant pivots or changes in ownership structure since its inception.Arrakis Therapeutics specializes in developing RNA-targeted small-molecule (rSM) medicines, a new class of genetic therapies aimed at treating various diseases. Their proprietary and partnered rSM medicines are designed to bind to RNA using small molecules, enabling the creation of oral medications for conditions such as myotonic dystrophy. They cater to pharmaceutical partners and research institutions primarily in North America and Europe, while also looking to expand into other international markets.Arrakis Therapeutics generates revenue through strategic partnerships and collaborations within the biopharmaceutical industry, focusing on B2B relationships with pharmaceutical companies and research organizations. Their revenue model includes milestone payments and royalties contingent upon the success of rSM medicines in research and development, with revenue anticipated from both upfront and ongoing payments following successful product launches.With the recent Series B funding raised in April 2019, Arrakis Therapeutics plans to utilize the USD 15.00 mn to advance its pipeline of novel RNA-targeted small molecules and reach clinical testing with one or more candidates. The company is targeting expansion into new geographic markets, with specific efforts aimed at increasing their presence in Europe and Asia by 2022. This strategy aligns with their goal of broadening access to their innovative therapies across multiple regions.

## Funding rounds

- Series B, Apr 10, 2019, $15M — Canaan Partners, HBM Partners, Alexandria Venture Investments, OUP (Osage University Partners), Nextech, GV, Omega Funds, Pfizer Venture Investments, VenBio, Bristol-Myers Squibb Company, Advent Life Sciences, Wuxi AppTec Group
- Series A, Feb 27, 2017, $13M — Canaan Partners, OUP (Osage University Partners), Pfizer Inc., Celgene, Advent Life Sciences

## Investors

- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series A, Series B
- OUP (Osage University Partners) (https://capitalatlas.ai/funds/oup-osage-university-partners) — Series A, Series B
- Pfizer Inc. — Series A
- Celgene — Series A
- Advent Life Sciences (https://capitalatlas.ai/funds/advent-life-sciences) — Series A, Series B
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B
- Nextech (https://capitalatlas.ai/funds/nextech) — Series B
- GV (https://capitalatlas.ai/funds/gv) — Series B
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series B
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series B
- VenBio (https://capitalatlas.ai/funds/venbio) — Series B
- Bristol-Myers Squibb Company — Series B
- Wuxi AppTec Group — Series B